Evidence map›Paper›PMID 37727442›Full record

ArticleMolecular therapy. Nucleic acids2023

Targeting microRNA-145-mediated progressive phenotypes of early bladder cancer in a molecularly defined

Kazuki Heishima, Nobuhiko Sugito, Chikara Abe, Akihiro Hirata, Hiroki Sakai, Yukihiro Akao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kazuki HeishimaThe United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Gifu, Japan.
Nobuhiko SugitoThe United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Gifu, Japan.
Chikara AbeDepartment of Physiology, Gifu University Graduate School of Medicine, Gifu, Gifu, Japan.
Akihiro HirataCenter for One Medicine Innovative Translational Research (COMIT), Gifu University, Gifu, Gifu, Japan.
Hiroki SakaiCenter for One Medicine Innovative Translational Research (COMIT), Gifu University, Gifu, Gifu, Japan.
Yukihiro AkaoThe United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Gifu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A progressive subclass of early-stage non-muscle-invasive bladder cancer (NMIBC) frequently recurs and progress into invasive carcinoma, thus decreasing the overall survival rate of NMIBC. However, therapeutic development for progressive NMIBC has been challenging due to the lack of molecularly validated

Indexed as

early bladder cancerearly bladder cancer rat modelintravesical therapymicroRNAmicroRNA-145MT: Non-coding RNAsNMIBCnon-muscle-invasive bladder cancer

Identifiers

PMID37727442
PMCPMC10505924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.